Skip to main content
SpringerLink
Log in

Pharmaceutical R&D: the road to positive returns

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Improving the return on small-molecule R&D.
Figure 2: Output of model.

Author information

Authors and Affiliations

  1. Eric David, M.D., Tony Tramontin, Ph.D., and Rodney Zemmel, Ph.D., are at McKinsey & Company, 55 East 52nd Street, New York, New York 10055, USA. Eric_David@mckinsey.com; Rodney_Zemmel@mckinsey.com,

    Eric David, Tony Tramontin & Rodney Zemmel

  2. Tony_Tramontin@mckinsey.com,

    Eric David, Tony Tramontin & Rodney Zemmel

Authors
  1. Eric David
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tony Tramontin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rodney Zemmel
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary information S1 (box)

Methodology to estimate the internal rate of return on R&D investments (PDF 296 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

David, E., Tramontin, T. & Zemmel, R. Pharmaceutical R&D: the road to positive returns. Nat Rev Drug Discov 8, 609–610 (2009). https://doi.org/10.1038/nrd2948

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2948

  • Springer Nature Limited

This article is cited by

Search

Navigation